Hillstream Biopharma (NASDAQ:CNTN) Director Sells $300,450.42 in Stock

Hillstream Biopharma Inc. (NASDAQ:CNTN) Director Gary Stetz sold 87,851 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $3.42, for a total value of $300,450.42. Following the completion of the transaction, the director directly owned 146,675 shares of the company’s stock, valued at approximately $501,628.50. The trade was a 37.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Hillstream Biopharma Stock Down 0.3%

Shares of NASDAQ:CNTN opened at $3.10 on Friday. The company’s 50-day simple moving average is $3.31. Hillstream Biopharma Inc. has a 1 year low of $1.08 and a 1 year high of $9.08. The firm has a market cap of $216.41 million, a price-to-earnings ratio of -2.70 and a beta of 1.44.

Hillstream Biopharma (NASDAQ:CNTN) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.23) EPS for the quarter.

Wall Street Analysts Forecast Growth

CNTN has been the subject of a number of research analyst reports. Wall Street Zen upgraded Hillstream Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings cut Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Hillstream Biopharma has an average rating of “Sell”.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.